A spontaneous recurrent seizure bioassay for anti-epileptogenic molecules.
Drug design in epilepsy is now tackling a new target--epileptogenesis. This is the process whereby a normal brain becomes susceptible to recurrent seizures. One of the stumbling blocks in the design and discovery of new chemical entities as antiepileptogenics is the implementation of an appropriate biological model. Current models, such as the maximal electroshock model, are models of seizures, not models of epileptogenesis. To develop such a model, we have extended and modified a chronic pilocarpine spontaneous recurrent seizure (SRS) model for the purposes of developing a bioassay with which to screen new compounds for putative antiepileptogenic bioactivity.
Lyon
Angela P
AP
Department of Chemistry, Queen's University, Kingston, Ontario, Canada.
Wainman
Dan
D
Marone
Sandra
S
Weaver
Donald F
DF
D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use*; D001681:Biological Assay / Q000379:methods*; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D004827:Epilepsy / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D010862:Pilocarpine / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012008:Recurrence
D000927:Anticonvulsants; D010862:Pilocarpine